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Cochrane Peripheral Vascular Diseases Review
Group: Review AbstractsIntroduction
The following abstracts are part of an ongoing series of
articles produced by the Cochrane Peripheral Vascular
Diseases Review Group, which is part of The Cochrane
Collaboration. The reviews are published in full in The
Cochrane Database of Systematic Reviews in The Cochrane
Library, a quarterly electronic journal available on CD-ROM
and via the Internet (http://www3.interscience.wiley.
com/cgi-bin/mrwhome/106568753/HOME). The electronic
format allows Cochrane reviews to accommodate new data
as they become available, making The Cochrane Library
a consistently up-to-date source of information over time.
Certain abstracts appearing in The Cochrane Database of
Systematic Reviews may be presented in a simpler, less
scientific format than the abstract presented here to
permit greater accessibility to the public. However, the
substance of both versions is the same. Cochrane reviews
are now indexed on MEDLINE.
If you are interested in conducting a Cochrane review or
contributing to the activities of the Cochrane Peripheral
Vascular Diseases Review Group, please contact:
Professor FGR Fowkes
Cochrane Peripheral Vascular Diseases Review Group
Public Health Sciences
University of Edinburgh
Teviot Place
Edinburgh EH8 9AG
Tel. þ44 (0) 131 650 3220
Fax. þ44 (0) 131 650 6904
Any feedback on Cochrane reviews should be made
through the feedback facility on The Cochrane Library, or
by contacting the group at the above address.
Abstracts
Abstract. Naftidrofuryl for intermittent claudication
de Backer TLM, Vander Stichele R, Lehert P, Van Bortel L.
Naftidrofuryl for intermittent claudication. Cochrane1078-5884/$36
doi:10.1016/j.ejvs.2009.06.019Database of Systematic Reviews 2008 , Issue 2 . Art. No.:
CD001368. DOI: 10.1002/14651858.CD001368.pub3 .
Background
Lifestyle changes and cardiovascular prevention measures
are a primary treatment for intermittent claudication (IC).
Symptomatic treatment with vasoactive agents (Anatomic
Therapeutic Chemical Classification (ATC) for medicines
from the World Health Organisation class CO4A) is
controversial.
Objectives
To evaluate evidence on the efficacy and safety of oral
naftidrofuryl (ATC CO4 21) versus placebo on the pain-free
walking distance (PFWD) of people with IC by using a meta-
analysis based on individual patient data (IPD).
Search strategy
The Cochrane Peripheral Vascular Diseases Group searched
their Trials Register (last searched December 2007) and
CENTRAL (last searched 2007, Issue 4). We searched
MEDLINE, EMBASE, International Pharmaceutical Abstracts,
the Science Citation Index and contacted the authors and
checked the reference lists of retrieved articles. We asked
the manufacturing company for IPD.
Selection criteria
We included only randomized controlled trials (RCTs) with
low ormoderate risk of bias for which the IPDwere available.Data collection and analysis
We collected data from the electronic data file or from the
case report formand checked the data by a statistical quality
control procedure. All randomized patients were analyzed
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geometric mean of the relative improvement in PFWD was
calculated for both treatment groups in all identified studies.
The effect of the drug was assessed compared with
placebo on final walking distance (WDf) using multilevel
and random-effect models and adjusting for baseline
walking distance (WD0). For the responder analysis, ther-
apeutic success was defined as an improvement of walking
distance of at least 50%.
Main results
We included seven studies in the IPD (nZ 1266 patients).
One of these studies (nZ 183) was only used in the sensi-
tivity analysis so that the main analysis included 1083
patients. The ratio of the relative improvement in PFWD
(naftidrofuryl compared with placebo) was 1.37 (95% confi-
dence interval (CI) 1.32 to 1.51, P< 0.001). The absolute
difference in responder rate, or proportion successfully
treated, was 22.3% (95% CI 17.1% to 27.6%). The calculated
number needed to treat was 4.5 (95% CI 3.6 to 5.8).
Authors’ conclusions
Naftidrofuryl has a statistically significant and clinically
meaningful effect of improving walking distance in the six
months after initiation of therapy for people with inter-
mittent claudication. Access by researchers to data from
RCTs that are suitable for IPD analysis should be possible
through repositories of data from pharmacological trials.
Regular formal appraisal of the balance of risk and benefit
is needed for older pharmaceutical products.
Abstract. Beta blockers for peripheral arterial disease
Paravastu SC, Mendonca D, Da Silva A. Beta blockers for
peripheral arterial disease. Cochrane Database of System-
atic Reviews 2005 , Issue 4 . Art. No.: CD005508. DOI:
10.1002/14651858.CD005508 .
Background
Beta (ß) blockers are indicated for use in coronary artery
disease (CAD). However, optimal therapy for people with
CAD accompanied by intermittent claudication has been
controversial due to the presumed peripheral haemody-
namic consequences of beta blockers, leading to worsening
symptoms of intermittent claudication.
Objectives
To quantify the potential harm of beta blockers onmaximum
walking distance, claudication distance, calf blood flow, calf
vascular resistance, and skin temperature when used in
patients with peripheral arterial disease (PAD).
Search strategy
The Cochrane Peripheral Vascular Diseases (PVD) Group
searched for publications describing randomised controlled
trials (RCTs) of beta blockers in PAD in their Trials Register
(last searched 6 May 2008) and the Cochrane CentralRegister of Controlled Trials (CENTRAL) (last searched The
Cochrane Library 2008, Issue 2). We handsearched relevant
journals and conference proceedings.
Selection criteria
Randomised controlled trials evaluating the role of both
selective (ß1) and non-selective (ß1 and ß2) beta blockers
compared with placebo. We excluded trials comparing
different types of beta blockers.
Data collection and analysis
Primary outcome measures were claudication distance in
metres, and the time to claudication in minutes, and
maximum walking distance in metres and minutes (as
assessed by treadmill).
Secondary outcome measures were calf blood flow
(ml/100 ml/min), calf vascular resistance, and skin
temperature (C).
Main results
We included six RCTs fulfilling the above criteria, with
a total of 119 patients. The beta blockers studied were
atenolol, propranolol, pindolol, and metoprolol. None of
the trials showed a statistically significant worsening effect
of beta blockers on either the primary or secondary
outcomes. There were no reports of any adverse events
with the beta blockers studied.
Authors’ conclusions
There is currently no evidence that beta blockers adversely
affect walking distance in people with intermittent clau-
dication. However, due to the lack of large published trials
beta blockers should be used with caution if clinically
indicated.
Abstract. Combined intermittent pneumatic leg compres-
sion and pharmacological prophylaxis for prevention of
deep venous thrombosis in high-risk patients
Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN,
Stansby GP, Reddy DJ. Cochrane Database of Systematic
Reviews 2005 , Issue 2. Art. No.: CD005258. DOI: 10.1002/
14651858.CD005258.
Background
It has been suggested that combined modalities (methods
of treatment) are more effective than single modalities in
preventing venous thromboembolism (defined as deep vein
thrombosis and pulmonary embolism, or both) in high-risk
patients.
Objectives
To assess the efficacy of intermittent pneumatic leg
compression combined with pharmacological prophylaxis
Cochrane Review Abstracts 625versus single modalities in preventing venous thromboem-
bolism in high-risk patients.
Search strategy
The Cochrane Peripheral Vascular Diseases (PVD) Group
searched their Specialized Register (last searched 17 July
2007) and the Cochrane Central Register of Controlled
Trials (CENTRAL) (last searched The Cochrane Library 2008,
Issue 3). We searched the reference lists of relevant arti-
cles to identify additional trials.
Selection criteria
Randomized controlled trials (RCTs) or controlled clinical
trials (CCTs) of combined intermittent pneumatic leg
compression and pharmacological interventions used to
prevent venous thromboembolism in high-risk patients.
Data collection and analysis
Data extraction was undertaken independently by two
review authors using data extraction sheets provided by the
Cochrane PVD Group.Main results
Eleven studies, six of them randomized controlled trials,
were identified. The trials included 7431 patients, in total.
Compared with compression alone, the use of combined
modalities reduced significantly the incidence of both
symptomatic pulmonary embolism (PE) (fromabout 3% to 1%;
odds ratio (OR) 0.39, 95% confidence interval (CI) 0.25 to
0.63) and deep vein thrombosis (DVT) (from about 4% to 1%;
OR 0.43, 95% CI 0.24 to 0.76). Compared with pharmaco-
logical prophylaxis alone, the use of combined modalities
significantly reduced the incidence of DVT (from 4.21% to
0.65%; OR 0.16, 95% CI 0.07 to 0.34) but the included studies
were underpowered with regard to PE. The comparison of
compression plus pharmacological prophylaxis versus
compression plus aspirin showed a non-significant reduction
in PE and DVT in favor of the former group. Repeat analysis
restricted to the RCTs confirmed the above findings.
Authors’ conclusions
Compared with compression alone, combined prophylactic
modalities decrease significantly the incidence of venous
thromboembolism. Compared with pharmacological prophy-
laxis alone, combined modalities reduce significantly the
incidence of DVT but the effect on PE is unknown. The
results of the current review support, especially in high-risk
patients, the use of combined modalities. More studies on
their role in the prevention of PE, compared with phar-
macological prophylaxis alone, are urgently needed.
Abstract. Low molecular weight heparin for prevention
of venous thromboembolism in patients with lower-leg
immobilizationTestroote M, Stigter WAH, de Visser DC, Janzing HMJ. Low
molecular weight heparin for prevention of venous throm-
boembolism in patients with lower-leg immobilization.
CochraneDatabase of Systematic Reviews 2008 , Issue 4 . Art.
No.: CD006681. DOI: 10.1002/14651858.CD006681.pub2.
Background
Immobilization of the lower leg is associated with venous
thromboembolism. Low molecular weight heparin (LMWH)
is an anticoagulant treatment which might be used in adult
patients with lower-leg immobilization to prevent deep
venous thrombosis and its complications.
Objectives
To investigate the current literature on thromboprophy-
lactic practice for patients with lower-limb injuries who are
immobilized in plaster casts or braces, to assess the need
for concrete guidelines, and to assess whether it is possible
to come to an evidence-based conclusion.Search strategy
The Cochrane Peripheral Vascular Disease Group searched
their Trials Register (last searched 20 May 2008) and the
Central Register of Controlled Trials (CENTRAL) (last
searched The Cochrane Library 2008, Issue 2). We searched
MEDLINE (until May 2008) and EMBASE (until May 2008) and
reference lists of articles. We contacted pharmaceutical
companies of LMWHs for relevant studies.Selection criteria
Randomized controlled trials (RCTs) and controlled clinical
trials (CCTs) that described thromboprophylaxis by means
of LMWH compared with no prophylaxis or placebo in adult
patients with lower-leg immobilization. Immobilization was
by means of a plaster cast or brace.Data collection and analysis
Two authors independently assessed trial quality and
extracted data. The review authors contacted the trial
authors for additional information. Statistical analysis was
carried out using Review Manager (RevMan 5).
Main results
We included six RCTs fulfilling the above criteria with
a total of 1490 patients. We found an incidence of venous
thromboembolism ranging from 4.3% to 40%, in patients
who had a leg injury that had been immobilized in a plaster
cast or a brace for at least one week and who received no
prophylaxis, or placebo. This number was significantly
lower in patients who received daily subcutaneous injec-
tions of LMWH during immobilization (event rates ranging
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interval (CI) 0.34 to 0.72; with minimal evidence of
heterogeneity with an I2 of 20%, PZ 0. 29). Comparable
results were seen in the following subcategories: patients
who had undergone operations, conservatively treated
patients, patients with fractures, patients with soft-tissue
injuries, patients with proximal thrombosis, patients with
distal thrombosis and patients with below-knee casts.Complications of major bleeding events were extremely
rare (0.3%) and there were no reports of heparin-induced
thrombocytopenia.
Authors’ conclusions
Use of LMWH in outpatients significantly reduces VTE when
immobilization of the lower leg is required.
